SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending due to excitement over its Legend app launch and nearing max token supply, sparking hopes for a supply shock and potential fintech integrations within the DeFi sector. However, community discussion is sharply divided, with optimistic price targets contrasting with significant concerns about the protocol's financial runway and governance, often in comparison to rivals like AAVE.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is currently soaring after securing FDA approval for YARTEMLEA, a groundbreaking first-in-class therapy for transplant-associated thrombotic microangiopathy (TA-TMA), a previously untreatable and often fatal condition. This pivotal approval, combined with an existing multi-billion dollar licensing deal with Novo Nordisk and significant short interest, has ignited immense excitement among investors who anticipate substantial long-term growth and a potential short squeeze. The community is actively discussing the company's strong de-risked financial position and the drug's unique market position, with many seeing this as the start of a new era for Omeros.

Bitwise 10 Crypto Index ETF - Common Shares Of Beneficial Interest

Bitwise 10 Crypto Index Fund

Bitwise 10 Crypto Index Fund is currently a focal point of intense community debate, primarily driven by a dominant bearish narrative forecasting a severe 'crypto winter' and Bitcoin plummeting to $20,000 by late 2026, based on historical 4-year cycles. Conversely, some investors highlight BITW's significant discount to its Net Asset Value and its ongoing efforts to convert to an ETP structure as potential catalysts for future gains, amidst widespread frustration over its market performance.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is currently trending due to recent exploration results announcing the discovery of the highest-grade silver in its Vortex system, sparking renewed interest in its Nevada gold and silver assets. This news, coupled with strong broader market demand for precious metals in industrial applications, has fueled community speculation about the company's long-term potential and the possibility of a significant market move, despite some ongoing debate regarding its production timeline and profitability.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending as investors react to its strategic pivot into powering the booming AI data center sector, notably through a significant $1.5 billion agreement with Applied Digital and other recent contract wins. The community is actively discussing whether its proven energy generation expertise positions it as a key 'picks and shovels' play for massive power demands, though concerns about valuation and market manipulation persist amidst recent contract announcements.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending following the FCC's decision to ban Chinese-made drones and the passage of the NDAA, which is expected to significantly boost spending on American defense technology. The community is actively debating the company's strong production capacity for its Black Widow drones and the promising outlook for its Blue Ops Unmanned Surface Vessels, while also expressing impatience for firm contract announcements and caution over past management communications.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending due to the recent FDA approval of AQVESME for alpha- and beta-thalassemia, making it the only approved medicine for these rare blood disorders. This development has sparked a significant volume surge and positive community discussion around the drug's unique market position, though some historical concerns regarding prior trial results for a separate indication and management performance are also noted.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is seeing intense conversation following Sanofi's agreement to acquire the company for $15.50 per share, an offer bolstering Sanofi's adult immunization portfolio with Dynavax's hepatitis B vaccine and shingles candidate. Community sentiment is largely mixed, with long-term investors expressing disappointment over the perceived undervaluation, contrasting with others who welcome the guaranteed exit amidst a significant volume surge. The acquisition has also spurred discussions about the board's fiduciary duties and the possibility of a competing bid.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending following its recent Q3 earnings, which highlighted improved financials and international market growth, alongside the debated non-inclusion of Vascepa on China's NRDL. Community sentiment is divided, with some investors expressing frustration over market valuation while others remain optimistic about ongoing legal developments, progress on a lymphatic release patent, and strategic positioning for a potential acquisition driven by the company's valuable cardiovascular asset.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

OPGN is trending as investors keenly follow ongoing SEC filings and strategic advancements to launch its AI-driven CapForce fintech platform, signaling potential steps towards Nasdaq relisting. The community is actively discussing hopes for a significant surge stemming from this pivot to digital investment banking, though skepticism remains due to the company's history of reverse splits and low trading volume in its current OTC Expert Market status.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Assenagon Asset Management S.A. Boosts Stock Position in CorVel Corp. $CRVL

Assenagon Asset Management S.A. raised its stake in CorVel Corp. (NASDAQ:CRVL - Free Report) by 68.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange...

Thrivent Financial for Lutherans Increases Stock Position in CorVel Corp. $CRVL

Thrivent Financial for Lutherans raised its stake in shares of CorVel Corp. (NASDAQ:CRVL - Free Report) by 187.9% in the 2nd quarter, according to the company in its most recent disclosure with the...

Neuberger Berman Group LLC Has $40.05 Million Stock Holdings in CorVel Corp. $CRVL

Neuberger Berman Group LLC trimmed its position in shares of CorVel Corp. (NASDAQ:CRVL - Free Report) by 53.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities...

CorVel (NASDAQ:CRVL) Hits New 12-Month Low - What's Next?

CorVel (NASDAQ:CRVL) Hits New 52-Week Low - What's Next...

CorVel is Now Oversold (CRVL)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

334,869 Shares in CorVel Corp. $CRVL Bought by Norges Bank

Norges Bank purchased a new stake in CorVel Corp. (NASDAQ:CRVL - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange...

JPMorgan Chase & Co. Decreases Stock Position in CorVel Corp. $CRVL

JPMorgan Chase & Co. trimmed its holdings in shares of CorVel Corp. (NASDAQ:CRVL - Free Report) by 14.8% during the 2nd quarter, according to the company in its most recent filing with the Securities...

American Century Companies Inc. Grows Position in CorVel Corp. $CRVL

American Century Companies Inc. grew its position in CorVel Corp. (NASDAQ:CRVL - Free Report) by 280.7% during the second quarter, according to the company in its most recent filing with the...

CorVel (NASDAQ:CRVL) Reaches New 52-Week Low - Here's What Happened

CorVel (NASDAQ:CRVL) Hits New 1-Year Low - Here's What Happened...

CorVel Corp. $CRVL Stock Holdings Lifted by XTX Topco Ltd

XTX Topco Ltd raised its position in CorVel Corp. (NASDAQ:CRVL - Free Report) by 128.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange...

CorVel Corp. engages in the provision of services to employers and payors in the risk management and insurance services arenas, including workers' compensation, general liability, auto liability, and hospital bill auditing and payment integrity. It operates through the Patient Management Services and Network Solutions Services segments. The Patient Management Services segment includes claims administration, utilization review, medical case management, and vocational rehabilitation. The Network Solutions Services segment consists of fee schedule auditing, hospital bill auditing, coordination of independent medical examinations, diagnostic imaging review services, and preferred provider referral services. The company was founded by V. Clemons Gordon Sr. in 1987 and is headquartered in Fort Worth, TX.

Current Price	$68.88
Prev Close	$68.04
Open	$68.00
Dividend Yield	0.00%
50-Day Moving Average	$72.59
Beta	0.71
Avg. Volume	170,707.74
PE Ratio	33.94

52-Week High	$128.61
52-Week Low	$66.49
Market Capitalization	$6B
EPS (Annual)	$1.83
Price to Book	9.74
Revenue Per Employee	$176,470.74
Enterprise Value/EBITDA	N/A

CRVL
Corvel Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRVL News

CRVLCorvel Corp.